

Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)

Technology appraisal guidance

Published: 27 July 2022

www.nice.org.uk/guidance/ta811

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments. Secura Bio has confirmed that it is withdrawing the evidence submission for the appraisal because the technology will not be launched in the UK for treating this indication.

Information

If NHS organisations wish to consider duvelisib for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4683-9

Accreditation

